ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 170 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $328 | -47.8% | 29,364 | 0.0% | 0.02% | -44.4% |
| Q2 2023 | $628 | -9.8% | 29,364 | +70.7% | 0.03% | -18.2% |
| Q1 2023 | $696 | -9.3% | 17,204 | +4.4% | 0.03% | -21.4% |
| Q4 2022 | $767 | -99.9% | 16,480 | -29.9% | 0.04% | -43.2% |
| Q3 2022 | $1,219,000 | -11.2% | 23,510 | -19.0% | 0.07% | -28.2% |
| Q2 2022 | $1,372,000 | +4.4% | 29,020 | +57.2% | 0.10% | +19.8% |
| Q1 2022 | $1,314,000 | +371.0% | 18,460 | +457.9% | 0.09% | -16.5% |
| Q2 2019 | $279,000 | -77.9% | 3,309 | -74.9% | 0.10% | -85.7% |
| Q1 2019 | $1,260,000 | -20.8% | 13,186 | -41.3% | 0.72% | +62.2% |
| Q4 2018 | $1,591,000 | +3.9% | 22,465 | +25.3% | 0.44% | +34.5% |
| Q3 2018 | $1,532,000 | +83.0% | 17,922 | +148.2% | 0.33% | +89.7% |
| Q2 2018 | $837,000 | +46.3% | 7,220 | +2.1% | 0.17% | +56.8% |
| Q1 2018 | $572,000 | – | 7,070 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,599,109 | $63,277,000 | 8.68% |
| SENZAR ASSET MANAGEMENT, LLC | 566,903 | $22,432,000 | 6.58% |
| Sarissa Capital Management LP | 105,000 | $4,155,000 | 1.60% |
| INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 136,637 | $5,407,000 | 1.41% |
| RA Capital Management | 250,000 | $9,893,000 | 1.17% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 110,515 | $4,373,000 | 0.99% |
| Ghost Tree Capital, LLC | 35,000 | $1,385,000 | 0.75% |
| WALL STREET ASSOCIATES | 159,100 | $6,296,000 | 0.65% |
| BAILARD, INC. | 91,500 | $3,621,000 | 0.56% |
| EAM Investors, LLC | 62,768 | $2,484,000 | 0.50% |